Crucell Left at the Altar

January 26th, 2009 | Sources: Wall Street Journal

Subjects:

One piece of fallout from the Pfizer-Wyeth hook up announced a few hours ago is that the latter will not be acquiring Crucell after all.

According to the an online story from the Wall Street Journal, “Crucell NV said Wyeth pulled out of friendly takeover talks with the Dutch vaccine maker.

Crucell admitted the discussions earlier this month, and people familiar with the matter at the time valued Crucell at$1.3 billion.”

A Pizaazz post, written before the Pfizer-Wyeth tie-up was made official and up for about an hour this morning, had speculated the Wyeth-Crucell deal might go ahead regardless of the larger circumstances, but that does not appear to be the case.  

We’ve pulled the original post and apologize for speculation that proved to be incorrect.


 

Add Your Comment

You must be logged in to post a comment.

We just want the site to look nice!
  • Comment Policy


    Pizaazz encourages the posting of comments that are pertinent to issues raised in our posts. The appearance of a comment on Pizaazz does not imply that we agree with or endorse it.

    We do not accept comments containing profanity, spam, unapproved advertising, or unreasonably hateful statements.



























Contact us if interested